Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705574 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT01705574 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 583 participants.
The verdict
NCT01705574, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) versus ritonavir (RTV)-boosted atazanavir (ATV/r) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in HIV-1 infected, antiretroviral treatment-naive adult women.
Interventions
- DRUG FTC/TDF
- DRUG ATV
- DRUG RTV
- DRUG E/C/F/TDF
- DRUG E/C/F/TDF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2012-10-24 |
| Est. Completion | 2018-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01705574
The ClinicalTrials.gov registry entry for NCT01705574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FTC/TDF is the first listed.
NCT01705574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01705574 about?
NCT01705574 is a clinical study titled "Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women". The primary objective of this study is to evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) versus ritonavir (RTV)-boosted atazanavir (ATV/r) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in HIV-1 infected, anti...
What is the current status of trial NCT01705574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2012-10-24. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT01705574?
The interventions under investigation include: FTC/TDF (DRUG), ATV (DRUG), RTV (DRUG), E/C/F/TDF (DRUG), E/C/F/TDF Placebo (DRUG).
Who is sponsoring clinical trial NCT01705574?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.